Shopping Cart
- Remove All
Your shopping cart is currently empty
TJ08 is a 1,2,5-trisubstituted benzimidazole derivative with anticancer properties that effectively induces G1/S phase blockade while promoting apoptotic effects in a variety of cancer cells.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $238 | In Stock | |
| 5 mg | $582 | In Stock | |
| 10 mg | $708 | In Stock | |
| 25 mg | $948 | In Stock |
| Description | TJ08 is a 1,2,5-trisubstituted benzimidazole derivative with anticancer properties that effectively induces G1/S phase blockade while promoting apoptotic effects in a variety of cancer cells. |
| In vitro | TJ08 (1-10 μM; 24 hours) induces apoptosis by altering mitochondrial membrane potential, triggering S-phase arrest, halting cancer cell progression, and causing upregulation of caspase activation and downregulation of anti-apoptotic BCl2 protein [1]. |
| Molecular Weight | 405.38 |
| Formula | C22H16FN3O4 |
| Cas No. | 2924274-19-9 |
| Smiles | O=C(C1=CC=C2C(N=C(N2CC3=CC=CC=C3)C4=CC([N+]([O-])=O)=C(F)C=C4)=C1)OC |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.